Sign in
BLTE Stock Price, Chart, Stats & News
Belite Bio, Inc
Save
Belite Bio, Inc (BLTE) does not currently pay a dividend.
6.71B
Market cap
–
Current P/E
434.78x
Forward P/E
BLTE chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -27.48% |
ROE | -42.65% |
D/E | 0.00x |
Interest coverage ratio | – |
BLTE valuation
P/E | – |
P/S | – |
P/B | 18.61x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | 3.14x |
EV multiple | -72.90x |
About
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Similar securities
Based on sector and market capitalization
Report issue